Eukaryotic initiation factor 4E (eIF-4E), a 25-kDa cap binding protein, delivers cellular mRNAs to the eIF4F translation initiation complex by binding the 5'-cap structure of these mRNAs. Studies suggested that increased expression and activity of eIF-4E might be one of the key effects on oncogene expression, resulting in neoplastic transformation. eIF-4E is overexpressed in many types of cancers, including carcinoma of the breast, colon, bladder, cervix, lung, and squamous cell carcinoma of the head and neck. Increased expression of eIF-4E has been associated with tumor progression in breast cancer, prostate cancer, and acute myeloid leukemia (AML).
Literature:
Manufacturer site:
eIF-4E (EP280)
Rabbit Monoclonal
Eukaryotic initiation factor 4E (eIF-4E), a 25-kDa cap binding protein, delivers cellular mRNAs to the eIF4F translation initiation complex by binding the 5'-cap structure of these mRNAs. Studies suggested that increased expression and activity of eIF-4E might be one of the key effects on oncogene expression, resulting in neoplastic transformation. eIF-4E is overexpressed in many types of cancers, including carcinoma of the breast, colon, bladder, cervix, lung, and squamous cell carcinoma of the head and neck. Increased expression of eIF-4E has been associated with tumor progression in breast cancer, prostate cancer, and acute myeloid leukemia (AML).
Rabbit Monoclonal
Eukaryotic initiation factor 4E (eIF-4E), a 25-kDa cap binding protein, delivers cellular mRNAs to the eIF4F translation initiation complex by binding the 5'-cap structure of these mRNAs. Studies suggested that increased expression and activity of eIF-4E might be one of the key effects on oncogene expression, resulting in neoplastic transformation. eIF-4E is overexpressed in many types of cancers, including carcinoma of the breast, colon, bladder, cervix, lung, and squamous cell carcinoma of the head and neck. Increased expression of eIF-4E has been associated with tumor progression in breast cancer, prostate cancer, and acute myeloid leukemia (AML).
